Navigating the NICU: How Stem Cell Research is Helping Premature Infants

Premature infants face life-threatening challenges, including underdeveloped lungs, fragile brains, and weak immune systems. Nearly 500,000 babies are born prematurely each year in the U.S., with NICU care costing an average of $3,000 per day. Advances in stem cell research, particularly using umbilical cord blood and placental tissue, are offering new ways to address complications like brain injuries, chronic lung disease, and severe inflammation. These therapies aim to repair damaged organs and improve long-term outcomes for preemies.

Key points:

• Premature birth risks: Respiratory distress, brain injuries, and intestinal inflammation are common.
• Stem cell potential: Umbilical cord blood and tissue stem cells can reduce inflammation and promote healing.
• Clinical findings: Stem cell treatments have shown improved survival rates and neurodevelopmental outcomes.
• Cord blood banking: Services like Americord provide families with the option to preserve stem cells for future therapies.

This article explores how stem cell therapies are reshaping NICU care, the science behind these treatments, and practical steps for cord blood banking.

Premature Birth and NICU Challenges

Premature birth, defined as delivery before 37 weeks of pregnancy, presents a host of medical challenges due to incomplete organ development. Globally, about 10% of all births - an estimated 15 million babies annually - are premature, requiring specialized care to survive and grow.

The hurdles these infants face are daunting. Their lungs often lack surfactant, a substance essential for keeping air sacs open and enabling proper breathing. Their brains are particularly fragile, making them vulnerable to bleeding and oxygen deprivation. Feeding can also be a struggle, as underdeveloped digestive systems make it difficult to coordinate sucking and swallowing. To make matters worse, their immature immune systems leave them defenseless against infections that would pose little risk to a full-term baby.

"Preterm neonates are among our most vulnerable citizens. Brain injury is far more common in preterm infants than at term and is associated with a greater risk of adverse outcomes." - Pediatric Research

The level of care required depends on how prematurely a baby is born. Late preterm infants (34–36 weeks) often need just a short stay in the NICU, primarily for feeding support, and their survival rates exceed 99%. On the other hand, babies born extremely early - before 28 weeks - face far greater risks. They often require ventilators, IV nutrition, and continuous monitoring, with survival rates ranging from 60% to 90%.

Health Challenges for Premature Infants

Respiratory issues are among the most pressing problems. Many preemies develop Respiratory Distress Syndrome (RDS) due to insufficient surfactant production. Apnea of Prematurity, where breathing pauses for over 20 seconds, is another common issue caused by immature brain function. Extended use of oxygen therapy or ventilators can lead to Bronchopulmonary Dysplasia (BPD), a chronic lung condition.

Brain injuries are another serious concern. Intraventricular Hemorrhage (IVH), or bleeding in the brain, can occur when delicate blood vessels rupture. Hypoxic-Ischemic Encephalopathy (HIE) results from a lack of oxygen reaching brain tissue, while White Matter Injury (WMI) damages connections between brain cells. These complications can lead to long-term conditions like cerebral palsy, developmental delays, or epilepsy.

Other organs also face challenges. Premature digestive systems are prone to Necrotizing Enterocolitis (NEC), a severe intestinal inflammation. Immature livers often struggle to process bilirubin, causing jaundice that may require phototherapy. Additionally, underdeveloped eyes are at risk for Retinopathy of Prematurity (ROP).

Research shows that brain injuries in preemies can continue to evolve weeks after the initial damage, entering a "tertiary phase" marked by prolonged inflammation and cellular loss. This extended timeline offers an opportunity for interventions, including experimental stem cell therapies, to mitigate long-term effects.

These health concerns demand immediate and specialized care in the NICU.

NICU Care for Preterm Infants

NICUs are designed to address the complex needs of premature infants. From the moment a preemie is born, a neonatal team works quickly to stabilize breathing, regulate body temperature, and support circulation - critical steps for survival.

Temperature control is a top priority since preemies lack the body fat needed to stay warm on their own. NICUs use incubators with controlled humidity or radiant warmers to prevent cold stress, which can drain the energy needed for healing and growth. For respiratory support, options range from CPAP (Continuous Positive Airway Pressure) machines to mechanical ventilators, depending on the baby's needs. Surfactant therapy is often administered directly into the lungs to help keep air sacs open and improve breathing.

Feeding is another significant challenge. Preemies born before 34–36 weeks often can't manage the coordination needed for sucking, swallowing, and breathing. Until they develop this ability, they receive nutrition through IV lines (parenteral nutrition) or feeding tubes (gavage feeding). Breast milk is highly encouraged because it contains antibodies that lower the risk of NEC and other infections.

Modern NICUs also emphasize family involvement in a baby's care. Skin-to-skin contact, or Kangaroo Care, has proven benefits, including stabilizing heart rate and breathing while fostering a stronger parent-child bond. According to the World Health Organization, this simple practice can reduce mortality in low-birth-weight infants by up to 40%. Additionally, NICUs create calming environments by dimming lights, minimizing noise, and scheduling care activities to allow for extended rest periods - measures that support brain development during this critical time.

This intensive care lays the groundwork for exploring advanced treatments, such as stem cell therapies, to improve long-term outcomes for premature infants.

Stem Cell Therapies for NICU Care

While traditional NICU care focuses on stabilizing premature infants, stem cell therapies aim to repair the underlying damage caused by prematurity. These treatments go beyond symptom management, addressing complications like brain injuries and lung disease at their source.

The science behind this lies in the body's natural ability to heal itself. Stem cells derived from umbilical cord blood and tissue have remarkable healing properties. They can travel directly to damaged organs, where they release growth factors and proteins that reduce inflammation, prevent cell death, and stimulate the infant's cells to regenerate. This is especially crucial for preemies, as their injuries often worsen during the "tertiary phase" - a critical period of weeks following birth, offering a narrow window for intervention.

A 2025 meta-analysis revealed that neonates treated with stem cell therapy were 1.89 times more likely to achieve positive neurodevelopmental outcomes. Additionally, survival rates for infants with Hypoxic-Ischemic Encephalopathy (HIE) reached 92% at 12 months, with 76% achieving Bayley scores of 85 or higher.

Cord Blood Stem Cells for Brain Development

Umbilical cord blood contains powerful stem cells capable of repairing brain damage caused by oxygen deprivation or bleeding. These cells are often administered intravenously and paired with therapeutic hypothermia (cooling) to treat conditions like Hypoxic-Ischemic Encephalopathy (HIE), White Matter Injury (WMI), and Intraventricular Hemorrhage (IVH).

The healing process involves several mechanisms. Stem cells migrate to injury sites, releasing factors like BDNF and NGF that promote neural regeneration. They also shift microglia - the brain's immune cells - from a harmful state to one that supports healing.

Research from March 2026 highlights how human umbilical cord mesenchymal stem cells can convert microglia from a pro-inflammatory (M1) state to an anti-inflammatory (M2) state. This shift is critical for preserving white matter connections, which are essential for normal brain function. Preclinical studies suggest that administering multiple doses of cord blood cells may yield better long-term neurological and behavioral outcomes compared to a single dose.

"Stem cell therapy appears safe and may improve neurodevelopmental outcomes in neonates with HIE." - Child's Nervous System

Mesenchymal Stem Cells for Lung Repair

Stem cell therapies also show promise in addressing respiratory challenges. Bronchopulmonary Dysplasia (BPD), a chronic lung condition, affects approximately 10,000 new infants annually in the U.S., with rates as high as 80% for babies born before 24 weeks of gestation. This condition comes with a staggering annual cost of $6 billion, making up nearly 25% of all pediatric healthcare expenses.

Mesenchymal stem cells from umbilical cord tissue are emerging as a potential solution for this debilitating condition. These cells work through paracrine signaling, releasing healing factors that reduce inflammation and promote lung growth during the critical post-birth tertiary phase. Rather than directly replacing damaged cells, they create an environment that allows the infant's lungs to repair themselves. Delivery methods include intravenous injections or direct administration into the lungs via a breathing tube.

A 2024 meta-analysis of preclinical studies found that therapy using umbilical cord blood significantly improved the development of alveoli - the tiny air sacs essential for breathing - and boosted angiogenesis, the formation of new blood vessels. The treatment also reduced harmful inflammatory cytokines while increasing anti-inflammatory ones, shifting the lung environment toward healing.

Researchers are now investigating extracellular vesicles (EVs), tiny particles secreted by stem cells that carry the same healing factors without the risks of tumor formation or immune rejection. Clinical trials are focusing on extremely vulnerable infants born at 23–24 weeks, where early findings suggest stem cell therapies could dramatically reduce the severity of BPD in this high-risk group.

Americord Registry Services for NICU Families

For families facing the challenges of premature birth, preserving stem cells at delivery provides a biological safety net that could be crucial for their child's future health. This proactive step aligns with the advancements in stem cell therapies that are reshaping care in NICUs. Americord Registry offers specialized banking services tailored to meet the unique needs of preterm infants, whose increased risk of complications makes early preservation especially impactful.

Americord's Banking Options

Americord provides a 4-in-1 collection kit, enabling the simultaneous preservation of cord blood, cord tissue, placental tissue, and exosomes - all from a single delivery. This is particularly beneficial for NICU families, as each component contains unique stem cells and healing factors that support lung and brain repair. These services build on the proven benefits of stem cell therapies for addressing complications often faced by premature infants.

Americord’s process is designed to accommodate delayed cord clamping, a practice recommended by the American College of Obstetricians and Gynecologists. After the recommended 30–60 second delay for preterm infants, Americord collects the remaining cord blood, ensuring therapeutic options are preserved for the future.

Using CryoMaxx™ Processing and minimal manipulation techniques, Americord stores cord blood in five-compartment bags and cord and placental tissues in five cryovials each. This approach ensures maximum viability and flexibility for future therapies.

Banking with Americord not only provides a genetic match for the child but also offers potential matches for close family members. With a 100% success rate for the 14 cord blood units released for autologous transplants and an industry-leading $110,000 engraftment guarantee, Americord stands out. Payment plans, starting at $145 per month for 24 months with 0% interest, make these services more accessible, even during the financial strain of a NICU stay, which averages $3,000 per day.

Americord Family Plans Comparison

Plan	Cord Blood	Cord Tissue	Placental Tissue	Exosomes	Maternal Exosomes	Best For
Essential	✓	-	-	-	-	Families prioritizing blood disorder coverage
Advanced	✓	✓	-	-	-	NICU families seeking lung and brain repair options
Complete	✓	✓	✓	-	-	Families wanting maternal therapeutic potential
Ultimate	✓	✓	✓	✓	-	Preterm families accessing cell-free therapies
Maximum	✓	✓	✓	✓	✓	Comprehensive protection for infant and mother

For preterm infants, the Advanced plan or higher is highly relevant. Cord tissue mesenchymal stem cells, included in these plans, are central to research on conditions like bronchopulmonary dysplasia and hypoxic-ischemic encephalopathy. The Ultimate and Maximum plans go a step further by including exosome banking, offering access to emerging cell-free therapies. Properly cryopreserved at -196°F, these cells can remain viable for over 200 years, ensuring long-term therapeutic potential.

These flexible plans not only address immediate health concerns but also prepare families for future breakthroughs in neonatal care. By integrating seamlessly with NICU strategies, they provide a foundation for both current treatments and future possibilities in stem cell therapy.

Future Stem Cell Therapies for Preterm Infants

The next decade promises significant advancements in NICU care, as clinical trials for stem cell therapies progress from focusing on safety to proving their large-scale effectiveness. Right now, there are eleven active clinical trials investigating treatments for bronchopulmonary dysplasia (BPD). These include three Phase I trials, five Phase II trials, and two Phase III trials, signaling that these therapies are moving closer to practical application.

One notable Phase III trial, led by Zhuxiao Ren (NCT04440670), is testing whether intravenous umbilical cord blood mononuclear cells can reduce moderate to severe BPD. Meanwhile, a Phase II trial by Cotten's team revealed promising results: 74% of infants treated with autologous cord blood cells combined with hypothermia showed normal development at one year, compared to just 41% of those treated with hypothermia alone. While these cellular therapies are making strides, researchers are now exploring cell-free alternatives.

One such approach involves exosomes - tiny vesicles that deliver healing proteins and genetic material without requiring full cell transplantation. Exosomes derived from full-term umbilical cords have shown potential in promoting lung development by activating the Wnt5a/ROCK1 pathway. Remarkably, these exosomes remain stable for up to seven days at 39°F, making them a promising option for future therapies.

Expanding the scope of stem cell applications, recent studies suggest that mesenchymal stem cells (MSCs) could provide timely rescue treatments for necrotizing enterocolitis (NEC) while also addressing related neuroinflammation. For example, a 2025 study by Indiana University researchers, led by the Argyro Kagia team, demonstrated that administering umbilical cord–derived MSCs after the onset of NEC improved clinical outcomes and reduced neuroinflammation in the brain's cortical region. This research underscores the potential of targeted stem cell therapies to address interconnected challenges, often referred to as the "gut-lung-brain axis." Additionally, Won Soon Park's team is conducting a Phase II trial (NCT02892953) to test the use of intracerebroventricular transplantation of umbilical cord blood–derived MSCs in preventing post-hemorrhagic hydrocephalus in infants who have experienced brain hemorrhages.

These advances point toward a future of personalized therapies tailored to each infant's unique needs. Clinicians may soon be able to screen a baby's cord blood for specific bioactive components and design individualized treatments. Stem cells preserved at birth could be used in various forms - whole cells, exosomes, or specialized supplements - to support vital organ development during the critical NICU period.

How to Bank Stem Cells with Americord

If you're planning to bank your baby's stem cells with Americord, it's best to start the process early in your pregnancy. This gives you enough time to enroll, choose a family plan, complete the necessary consent forms, and receive your collection kit before your due date. Once you've got your kit, the collection process happens during delivery.

The actual collection is quick and completely non-invasive for both mom and baby. Right after delivery, your healthcare provider collects blood from the umbilical cord and tissue from the cord itself after it’s clamped. This step doesn’t interfere with your delivery or delay those first precious moments of skin-to-skin bonding. As Sean Daneshmand, MD, Founder of Miracle Babies, puts it:

"The stem cells in cord blood and cord tissue can be collected easily at the time of birth. They are a resource that is available to every child born that would otherwise be discarded."

This simple process ensures that important stem cells are preserved without disrupting the post-birth experience.

Once the collection is complete, you’ll use the prepaid medical courier included in your kit to send the samples to Americord’s lab. There, the samples are processed using CryoMaxx™ - a specialized method designed to recover as many stem cells as possible. The stem cells are then stored in 5-compartment vials, allowing for easy access to individual portions if needed for future therapies.

To make sure everything goes smoothly, confirm that your hospital supports cord blood collection and let your healthcare team know about your plans ahead of time. This preparation ensures everyone is ready on delivery day, giving you peace of mind that your baby’s stem cells will be safely preserved for potential future treatments.

Conclusion

The strides in NICU care and stem cell therapies highlighted earlier continue to bring hope for better outcomes in premature infants. Premature birth comes with many challenges, but advances in stem cell research are reshaping how NICU care is approached. For instance, cord blood stem cells may aid brain development in infants with hypoxic ischemic encephalopathy (HIE), while mesenchymal stem cells show promise in repairing lung tissue in babies suffering from bronchopulmonary dysplasia (BPD). A clinical study revealed that 74% of infants treated with their own cord blood cells alongside hypothermia showed normal development at one year, compared to only 41% in those who received hypothermia alone [1].

Banking your baby's stem cells provides an opportunity to save a resource that might otherwise go unused. As Dr. Sean Daneshmand, MD, Founder of Miracle Babies, explains:

"The potential to use the child's own stem cells to produce better clinical outcomes in premature infants is an exciting and promising concept that will be better understood as more studies are conducted and completed."

Americord simplifies this process with processing fees ranging from $1,500 to $3,000 and annual storage costs between $175 and $250. Their lifetime storage plans can save families up to 69% compared to annual fees, and flexible payment options like FSAs or HSAs can help cover expenses.

Americord’s family plans offer flexible and thorough banking solutions tailored to your newborn’s needs. By combining advanced science with practical planning, families can prepare for the future. With nearly 1 in 8 babies in the U.S. born prematurely, taking steps now to bank stem cells could play a critical role in safeguarding your child’s health.

FAQs

Are stem cell treatments for preemies available now, or only in trials?

Stem cell treatments for premature infants are currently offered mainly through clinical trials and research programs. Though the results so far are encouraging, these treatments haven’t yet become standard medical practice. Researchers are actively investigating how stem cells might help with challenges such as lung and brain development in premature babies.

How could cord blood or tissue stem cells help with brain or lung injury?

Cord blood and tissue stem cells hold promise for addressing brain and lung injuries in premature infants. These stem cells have the ability to aid tissue repair and minimize inflammation. For brain injuries like hypoxic-ischemic encephalopathy, they play a role in supporting neurological recovery. Similarly, in lung conditions such as bronchopulmonary dysplasia (BPD), they may help regenerate lung tissue and promote healthy development. Storing cord blood and tissue could provide access to these cutting-edge regenerative treatments.

When should I enroll with Americord to bank cord blood and tissue?

Enrolling with Americord right after your baby is born is highly recommended. The ideal window for collecting cord blood and tissue is within the first few days, as this ensures the stem cells are preserved quickly and efficiently. Signing up early simplifies the process and guarantees the collection happens on time for the best possible outcomes.